Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 2/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.41 |
| ▸ | MLLT3 | P42568 | 2/20 | 0.39 |
| ▸ | MLLT1 | Q03111 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30797720 | 1.00 | ICMT (0.54) | ICMTFGFR1IGF1ROPRM1MLLT3 | |
| SCHEMBL27736889 | 0.76 | ICMT (0.49) | ICMTIGF1RKCNH2HPGD | |
| SCHEMBL30797739 | 0.75 | ICMT (0.59) | ICMTMEN1KMT2AKCNH2 | |
| SCHEMBL20817524 | 0.75 | ICMT (0.59) | ICMTMEN1KMT2AKCNH2 | |
| SCHEMBL30798095 | 0.75 | ICMT (0.59) | ICMTMEN1KMT2AKCNH2 | |
| SCHEMBL20817526 | 0.75 | ICMT (0.59) | ICMTMEN1KMT2AKCNH2 | |
| SCHEMBL20817569 | 0.75 | ICMT (0.59) | ICMTMEN1KMT2AKCNH2 | |
| SCHEMBL30797803 | 0.74 | CYP3A4 (0.57) | ICMTFGFR1OPRM1ESR1ESR2 | |
| SCHEMBL3507152 | 0.74 | CYP3A4 (0.57) | ICMTFGFR1OPRM1ESR1ESR2 | |
| SCHEMBL14498657 | 0.74 | FGFR1 (0.47) | FGFR1OPRM1MEN1KMT2AESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111344284-B | Compounds useful as inhibitors of isoprene cysteine carboxymethyltransferase | 新加坡科技研究局 | 2024-03-12 | — | — | CN | disclosed |
| US-11834430-B2 | Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-12-05 | — | — | US | disclosed |
| US-11834430-B2 | Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-12-05 | — | — | US | disclosed |
| US-11834430-B2 | Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-12-05 | — | — | US | disclosed |
| US-20210130317-A1 | Compounds Useful as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-05-06 | — | — | US | disclosed |
| US-20210130317-A1 | Compounds Useful as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-05-06 | — | — | US | disclosed |
| EP-3681878-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE | Agency for Science, Technology and Research (SG) | 2020-07-22 | — | — | EP | disclosed |
| CN-111344284-A | Compounds useful as inhibitors of isoprene cysteine carboxymethyltransferase | 新加坡科技研究局 | 2020-06-26 | — | — | CN | disclosed |
| WO-2019054944-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-21 | — | — | WO | disclosed |
| WO-2019054944-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130317-A1 | Compounds Useful as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase | ICMT, INMT, BHMT | ICMT 1/4885FGFR1 4109/4885IGF1R 2476/4885 |
| US-11834430-B2 | Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase | ICMT, INMT, BHMT | ICMT 1/4885FGFR1 4109/4885IGF1R 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.